The Deep Dive is stepping up our programming. We’re upgrading our Canadian small cap coverage from written to visual, hitting investors with a double dose of market insights to provide a special look into just what’s happening in the Canadian public markets.
Our first series, referred to as The Deep Dive Spotlights, is providing exclusive industry insights from executives, insiders, technicians, specialists and more. The aim is to provide an inside look at just what happens in the small cap investment space, from operations to board rooms decisions and more.
To kick start the Spotlight series, we spent some time catching up with Chris Naprawa, President of Khiron Life Sciences.
Khiron Life Sciences (TSXV: KHRN) is a vertically integrated global medical and CPG cannabis company with core operations in Latin America and Europe. They have distribution throughout various countries in Latin America, along with activity in North America and Europe.
The company is licensed in Colombia for the cultivation, production, domestic distribution, and international export of both low and high THC medical cannabis products from Colombia to the UK, to Peru and Uruguay/Brazil.
Their business breaks down into three main segments: Medical Cannabis Products, Health Services – Where they operate their own network of medium complexity health centres under the brands ILANS and Zerenia, and Wellbeing Products – The company focuses on delivering the benefits of CBD and hemp across an array of various branded consumer packaged goods, such as its Kuida cosmetics line with sales in Colombia, UK and US.
As The Deep Dive has profiled in the past, Khiron stands out against the other Latin American issuers, based on the strength of their balance sheet, overall sales, and P/S sales metrics. The company is still early in their sales ramp and just starting to scale.
Join us as Chris outlines how Khiron plans to become a global leader within their space.
FULL DISCLOSURE: Khiron Life Sciences is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Khiron Life Sciences on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
